(Q43136343)

14 November 2017

title

Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial (English)

1 reference

multicenter clinical trial

14 November 2017

main subject

1 reference

1 reference

1 reference

6

Kazunari Murakami

1 reference

14 November 2017

Toshifumi Ohkusa

1

1 reference

14 November 2017

Kimitoshi Kato

2

1 reference

14 November 2017

Shuichi Terao

3

1 reference

14 November 2017

Toshimi Chiba

4

1 reference

14 November 2017

Katsuhiro Mabe

5

1 reference

14 November 2017

Yuji Mizokami

7

1 reference

14 November 2017

Toshiro Sugiyama

8

1 reference

14 November 2017

Akinori Yanaka

9

1 reference

14 November 2017

Yoshiaki Takeuchi

10

1 reference

14 November 2017

Shigeru Yamato

11

1 reference

14 November 2017

Tetsuji Yokoyama

12

1 reference

14 November 2017

Isao Okayasu

13

1 reference

14 November 2017

Sumio Watanabe

14

1 reference

14 November 2017

Hisao Tajiri

15

1 reference

14 November 2017

Nobuhiro Sato

16

1 reference

14 November 2017

Japan UC Antibiotic Therapy Study Group

17

1 reference

14 November 2017

language of work or name

English

0 references

publication date

9 March 2010

1 reference

The American Journal of Gastroenterology

14 November 2017

published in

1 reference

14 November 2017

volume

105

1 reference

14 November 2017

issue

8

1 reference

14 November 2017

page(s)

1820-1829

1 reference

Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Resistance of germfree rats to indomethacin-induced intestinal lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

An antibiotic-responsive mouse model of fulminant ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Cortisone in ulcerative colitis; final report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Intensive intravenous regimen for severe attacks of ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Mucosa-associated bacteria in ulcerative colitis before and after antibiotic combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Microbes in gastrointestinal health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Infectious gastroenteritis and risk of developing inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.84

21 January 2018

Identifiers

DOI

10.1038/AJG.2010.84

1 reference

14 November 2017

1 reference